Événements S-GE Facteurs de succès clés pour faire des affaires au Japon Apr 23, 2024 10:15–12:10 Zürich Switzerland
Evento S-GE Fattori chiave di successo per fare affari in Giappone Apr 23, 2024 10:15–12:10 Zürich Switzerland
SWISS Pavilion SWISS BIOTECH Pavilion @ BIO-Asia Taiwan 2024 Jul 24, 2024–Jul 28, 2024 Nangang District Taiwan
SWISS Pavilion SWISS BIOTECH Pavilion @ BIO-Asia Taiwan 2024 Jul 24, 2024–Jul 28, 2024 Nangang District Taiwan
Event S-GE Schlüssel zum Erfolg: Strategische Faktoren für Geschäftsaktivitäten in Japan Apr 23, 2024 10:15–12:10 Zürich Switzerland
News Mar 26, 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
SWISS Pavilion SWISS BIOTECH Pavilion @ BIO-Asia Taiwan 2024 Jul 24, 2024–Jul 28, 2024 Nangang District Taiwan
Unternehmerreisen Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing Jun 24, 2024–Jun 28, 2024 China
Actualités Apr 17, 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Voyages pour PME Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing Jun 24, 2024–Jun 28, 2024 China
News Jan 10, 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
Viaggi per imprenditori Fact Finding Mission: Chongqing, Dalian/Liaoyang & Pechino Jun 24, 2024–Jun 28, 2024 China
News Dec 19, 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
News May 10, 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...